Atlas Venture Opportunity Fund II, L.P.

This profile gathers the share dealings of Atlas Venture Opportunity Fund II, L.P. across 3 companies, led by Day One Biopharmaceuticals, Inc., Dyne Therapeutics, Inc. and Korro Bio, Inc. Over a trading history stretching from 17 June 2022 to 22 April 2024, the count stands at 3 filings.

Every open-market trade on record is a purchase: 3 purchases worth €21.3M, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2024: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €9.5M. Clusters matter here: 2 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 23 April 2024 with an open-market purchase (€939k) in Korro Bio, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.